Navigation Links
Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Jane Green, Kosan's Vice President, Corporate Communications, will present at the Leerink Swann Solid Tumors Roundtable Conference in New York at the Grand Hyatt Hotel on Friday, May 9, 2008 at 11:10 a.m. EDT. A live webcast of the presentation can be accessed through

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at A recorded replay of the presentations will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
4. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
5. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
6. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
7. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
8. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
9. Kosan Announces February 28, 2008 Conference Call and Webcast
10. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
11. Kosan Announces Third Quarter 2007 Financial Results
Post Your Comments:
(Date:12/1/2015)... -- Today the Allen Institute announced the opening of ... South Lake Union neighborhood, the city,s biotechnology hub. Located ... Avenue North, the 270,000 square foot life sciences building ... and the Allen Institute for Cell Science. ... Allen Institute. "We started by building a map of ...
(Date:12/1/2015)... Dec. 1, 2015 Frost & Sullivan ... This program addresses ways companies can innovate and ... --> ... --> ... as well as the disrupting factors altering the ...
(Date:12/1/2015)... , Dec. 01, 2015 ... the addition of the "2016 Europe ... Forecasts, Innovative Technologies, Competitive Strategies, Opportunities for ... to their offering. --> ... "2016 Europe Cell Surface Markers: Country ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... its best selling system laboratory animal colony management software solution, ezColony®, is now ... in on-site IT resources., , Many organizations are moving ...
Breaking Biology Technology:
(Date:10/29/2015)... MINNETONKA, Minn. , Oct. 29, 2015   ... that supports the entire spectrum of clinical research, is ... the Minnesota High Tech Association (MHTA) as one of ... in the "Software – Small and Growing" category. The ... and individuals who have shown superior technology innovation and ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
Breaking Biology News(10 mins):